Kamada Total Liabilities
Kamada total liabilities. Based on the latest financial reports, Kamada (KMDA) has total liabilities worth ILA111.98 Million ILA (≈ $300.21K USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See how many days can Kamada fund operations to measure how many days the company can operate on defensive assets alone.
Total Liabilities of Kamada (2006–2024)
Total liabilities of Kamada from 2006 to 2024. This chart illustrates how Kamada's total liabilities have evolved over time, based on quarterly financial data. Check financial resilience of Kamada to evaluate the company's liquid asset resilience ratio.
Kamada Competitors by Total Liabilities
The table below lists competitors of Kamada ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Qingdao Richen Food Co Ltd
SHG:603755
|
China | CN¥350.17 Million |
|
Earth-Panda Advanced Magnetic Material Co Ltd
SHG:688077
|
China | CN¥1.76 Billion |
|
Tubacex S.A
MC:TUB
|
Spain | €798.68 Million |
|
Nel ASA
OL:NEL
|
Norway | Nkr1.04 Billion |
|
Guangdong Huafeng New Energy Technology Co Ltd
SHE:002806
|
China | CN¥844.02 Million |
|
Hunan Resun Co Ltd
SHE:001218
|
China | CN¥802.14 Million |
|
Zhengzhou J and T Hi Tech Co
SHE:300845
|
China | CN¥195.24 Million |
|
Jiangsu Jiuwu Hi-Tech Co Ltd
SHE:300631
|
China | CN¥661.26 Million |
Liability Composition Analysis (2006–2024)
This chart breaks down Kamada's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Kamada (KMDA) total assets.
Liquidity & Leverage Metrics
Kamada Total Liabilities Ratios Explained
Kamada total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.03 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.42 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.30 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Kamada's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Kamada (2006–2024)
The table below shows the annual total liabilities of Kamada from 2006 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | ILA112.79 Million ≈ $302.39K |
+1.72% |
| 2023-12-31 | ILA110.89 Million ≈ $297.28K |
-24.24% |
| 2022-12-31 | ILA146.36 Million ≈ $392.38K |
+3.18% |
| 2021-12-31 | ILA141.84 Million ≈ $380.28K |
+342.89% |
| 2020-12-31 | ILA32.03 Million ≈ $85.86K |
-16.77% |
| 2019-12-31 | ILA38.48 Million ≈ $103.16K |
+49.49% |
| 2018-12-31 | ILA25.74 Million ≈ $69.01K |
-21.09% |
| 2017-12-31 | ILA32.62 Million ≈ $87.45K |
-1.02% |
| 2016-12-31 | ILA32.95 Million ≈ $88.35K |
+11.76% |
| 2015-12-31 | ILA29.48 Million ≈ $79.05K |
-23.66% |
| 2014-12-31 | ILA38.62 Million ≈ $103.55K |
-21.83% |
| 2013-12-31 | ILA49.41 Million ≈ $132.46K |
-18.63% |
| 2012-12-31 | ILA60.72 Million ≈ $162.79K |
-3.27% |
| 2011-12-31 | ILA62.78 Million ≈ $168.30K |
-3.47% |
| 2010-12-31 | ILA65.03 Million ≈ $174.36K |
+98.51% |
| 2009-12-31 | ILA32.76 Million ≈ $87.83K |
+11.36% |
| 2008-12-31 | ILA29.42 Million ≈ $78.87K |
-48.56% |
| 2007-12-31 | ILA57.19 Million ≈ $153.32K |
+33.60% |
| 2006-12-31 | ILA42.80 Million ≈ $114.76K |
-- |
About Kamada
Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its products include KAMRAB/KEDRAB indicated as prophylaxis of rabies; CYTOGAM for prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmuniza… Read more